Intra-Cellular Therapies v. Hetero: ANDA Patent Consolidation in Lumateperone Litigation
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Intra-Cellular Therapies, Inc. v. Hetero USA, Inc. |
| Case Number | 3:24-cv-04317 (Consolidated under 24-4264) |
| Court | District of New Jersey |
| Duration | March 2024 – August 2024 130 days |
| Outcome | Procedural Consolidation |
| Patents at Issue | |
| Accused Products | CAPLYTA® (lumateperone) capsules (10.5 mg, 21 mg, 42 mg) |
Case Overview
The Parties
⚖️ Plaintiff
New York-based biopharmaceutical company specializing in central nervous system (CNS) disorders. CAPLYTA® (lumateperone) is its flagship commercial product, FDA-approved for schizophrenia and bipolar depression.
🛡️ Defendant
Part of the Hetero Group, one of India’s largest generic pharmaceutical manufacturers, whose ANDA filing targets CAPLYTA® (lumateperone) capsules before patent expiry.
The Patents at Issue
This multi-front pharmaceutical patent infringement battle involves ten patents, covering compound chemistry, formulation, dosing regimens, and method-of-treatment claims for lumateperone. These collectively form a multi-layered IP fortress, typical of branded CNS pharmaceutical portfolios. Notably, USRE048839E is a reissue patent, signaling USPTO-level post-grant refinement of claim scope.
- • US11026951B2 — Compound chemistry and related claims
- • US10695345B2 — Formulation and composition claims
- • US10960009B2 — Method of treatment claims for CNS disorders
- • US9956227B2 — Dosing regimens
- • US11690842B2 — Further compound and formulation aspects
- • US11753419B2 — Additional method of use claims
- • US8648077B2 — Original composition of matter
- • US11052084B2 — Polymorphs or other solid forms
- • US11806348B2 — Specific formulations or delivery systems
- • USRE048839E — Reissue patent with refined claim scope
Developing a CNS drug?
Check if your compound or formulation might infringe these or related patents before clinical trials.
The Verdict & Legal Analysis
Outcome: Administrative Consolidation
Case No. 3:24-cv-04317 was administratively closed on August 5, 2024, after just 130 days. This was not a dismissal or defeat, but part of a seven-case judicial consolidation under lead action Civil Action No. 24-4264. This is not a merits determination—no infringement finding, validity ruling, or damages award has been issued. The case remains active in substance under the lead consolidated docket, preserving all parties’ substantive rights.
Critically, the consolidation order explicitly preserved each party’s right to request separate trials under Federal Rule of Civil Procedure 42(b), maintaining procedural flexibility should patent-specific or defendant-specific issues require individualized adjudication.
Verdict Cause Analysis: Consolidation as Litigation Strategy
The consolidation of seven parallel ANDA actions against multiple generic defendants is a recognized and strategically significant procedural mechanism in Hatch-Waxman litigation. This outcome reflects sophisticated judicial management to maximize judicial economy, ensure claim construction uniformity, and drive discovery efficiency. The New Jersey District Court’s active management reflects its institutional expertise in such complex pharmaceutical patent disputes.
The reissue patent (USRE048839E) among the asserted patents warrants particular attention. Reissue patents, having undergone post-grant claim revision, carry specific prosecution history estoppel implications that can affect both the doctrine of equivalents analysis and intervening rights defenses. The multi-strength dosage form assertion (10.5 mg, 21 mg, 42 mg) also suggests method-of-treatment and dosing claims, which can present distinct non-infringement arguments tied to label carve-outs under Caraco Pharmaceutical Laboratories v. Novo Nordisk.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in CNS pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 10 asserted patents in this CNS space
- See which companies are most active in lumateperone IP
- Understand claim scope and prosecution history
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your compound structure or formulation details
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Lumateperone compound and formulations
10 Patents Asserted
Covering compound, formulation, methods
Design-Around Options
Complex due to multi-layered IP fortress
✅ Key Takeaways
Multi-defendant ANDA consolidations under a lead docket are efficient but require proactive management of defendant-specific claim differentiation strategies.
Search related case law →Reissue patents in an asserted portfolio require dedicated prosecution history analysis for intervening rights and estoppel defenses.
Explore precedents →Rule 42(b) trial severance rights, explicitly preserved here, are a critical negotiating and tactical tool in consolidated ANDA proceedings.
View procedural rules →New Jersey District Court remains a strategically preferred venue for complex Hatch-Waxman pharmaceutical patent litigation.
Explore court dockets →Frequently Asked Questions
Ten patents are asserted, including US11026951B2, US10695345B2, US10960009B2, US9956227B2, US11690842B2, US11753419B2, US8648077B2, US11052084B2, US11806348B2, and reissue patent USRE048839E — collectively covering lumateperone’s compound, formulation, and method-of-use claims.
The case was administratively closed following judicial consolidation into lead action Civil Action No. 24-4264, which manages seven parallel ANDA patent infringement actions against multiple generic manufacturers. No merits determination was issued.
All substantive patent infringement issues will be resolved through the consolidated lead action, making its outcome determinative for the broader generic entry timeline for CAPLYTA® lumateperone capsules.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Full-Text Database (via Google Patents)
- PACER Federal Court Records
- FDA ANDA Paragraph IV Certification Overview
- Cornell Legal Information Institute — Caraco Pharmaceutical Laboratories v. Novo Nordisk
- United States District Court, District of New Jersey
- PatSnap — IP Intelligence Solutions for Pharmaceutical Companies
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.